Moderna (MRNA) Capital Expenditures (2018 - 2026)

Moderna (MRNA) has 9 years of Capital Expenditures data on file, last reported at $62.0 million in Q1 2026.

• Capital Expenditures for Q1 2026 came in at $62.0 million, up 24.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $204.0 million (up 264.29% YoY), and the FY2025 annual result was $192.0 million, up 97.94% from the prior year.
• Capital Expenditures advanced to $62.0 million in Q1 2026 per MRNA's latest filing, from $39.0 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $287.0 million in Q2 2024 and troughed at -$300.0 million in Q3 2024.
• A 5-year average of $32.5 million and a median of $43.0 million in 2023 frame the typical range for Capital Expenditures.
• On a YoY basis, Capital Expenditures climbed as much as 4000.0% in 2024 and fell as far as 797.67% in 2024.
• A 5-year view of Capital Expenditures shows it stood at -$8.0 million in 2022, then slumped by 125.0% to -$18.0 million in 2023, then surged by 205.56% to $19.0 million in 2024, then soared by 105.26% to $39.0 million in 2025, then jumped by 58.97% to $62.0 million in 2026.
• Business Quant data shows MRNA's Capital Expenditures at $62.0 million in Q1 2026, $39.0 million in Q4 2025, and $106.0 million in Q3 2025.